NiSource Inc. (NI) EPS Estimated At $0.06; Profile of 2 Analysts Covering Orexigen Therapeutics, Inc. (OREX)

October 13, 2017 - By Stephen Andrade

Among 5 analysts covering Orexigen Therapeutics (NASDAQ:OREX), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Orexigen Therapeutics had 12 analyst reports since August 5, 2015 according to SRatingsIntel. As per Wednesday, August 5, the company rating was upgraded by Zacks. The firm earned “Buy” rating on Saturday, August 8 by Piper Jaffray. The firm has “Market Perform” rating given on Wednesday, March 16 by JMP Securities. On Tuesday, October 6 the stock rating was maintained by Piper Jaffray with “Overweight”. The rating was downgraded by Wells Fargo to “Market Perform” on Friday, December 4. The firm has “Buy” rating by JP Morgan given on Monday, August 10. As per Friday, December 11, the company rating was reinitiated by Bank of America. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, November 6. The firm has “” rating by RBC Capital Markets given on Tuesday, September 15. See Orexigen Therapeutics, Inc. (NASDAQ:OREX) latest ratings:

Analysts expect NiSource Inc. (NYSE:NI) to report $0.06 EPS on November, 7.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.06 EPS. NI’s profit would be $19.53 million giving it 110.96 P/E if the $0.06 EPS is correct. After having $0.10 EPS previously, NiSource Inc.’s analysts see -40.00% EPS growth. About 1.54M shares traded. NiSource Inc. (NYSE:NI) has risen 5.02% since October 13, 2016 and is uptrending. It has underperformed by 11.68% the S&P500.

About 4.28 million shares traded or 4765.18% up from the average. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has declined 15.00% since October 13, 2016 and is downtrending. It has underperformed by 31.70% the S&P500.

Orexigen Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $30.40 million. The Firm is focused on the treatment of obesity. It currently has negative earnings. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Since May 11, 2017, it had 0 insider buys, and 4 insider sales for $2.19 million activity. Brown Donald Eugene sold 6,906 shares worth $176,172. 38,550 NiSource Inc. (NYSE:NI) shares with value of $934,912 were sold by Sistovaris Violet. Stanley Jimmie L also sold $899,906 worth of NiSource Inc. (NYSE:NI) on Thursday, May 11. Vegas Pablo sold $180,864 worth of NiSource Inc. (NYSE:NI) on Tuesday, May 23.

Investors sentiment decreased to 0.99 in 2017 Q2. Its down 0.16, from 1.15 in 2017Q1. It dropped, as 27 investors sold NiSource Inc. shares while 141 reduced holdings. 47 funds opened positions while 120 raised stakes. 258.78 million shares or 0.42% less from 259.88 million shares in 2017Q1 were reported. Gam Hldg Ag holds 0.03% or 69,166 shares. Aristotle Boston Limited Liability Com has 0.22% invested in NiSource Inc. (NYSE:NI). Cleararc Capital Inc reported 7,923 shares. Carlson Ltd Partnership holds 0.39% or 1.08 million shares. Fifth Third National Bank accumulated 13,072 shares. Goldman Sachs Gp reported 3.31M shares stake. Vanguard Group Inc Inc owns 33.91M shares. Suntrust Banks reported 19,537 shares. Omers Administration Corp has invested 0.01% in NiSource Inc. (NYSE:NI). Exxonmobil Investment Mngmt Tx owns 62,101 shares. Ameritas Inv Inc reported 7,702 shares or 0.01% of all its holdings. Pioneer Invest Mgmt Incorporated owns 0.09% invested in NiSource Inc. (NYSE:NI) for 1.03 million shares. Sector Pension Inv Board invested 0.01% in NiSource Inc. (NYSE:NI). Cohen Mgmt reported 0.13% of its portfolio in NiSource Inc. (NYSE:NI). Jane Street Group Inc Limited Liability holds 0% or 10,796 shares.

Among 13 analysts covering Nisource Inc. (NYSE:NI), 5 have Buy rating, 0 Sell and 8 Hold. Therefore 38% are positive. Nisource Inc. had 24 analyst reports since August 20, 2015 according to SRatingsIntel. On Tuesday, June 27 the stock rating was downgraded by Credit Suisse to “Sell”. The stock has “Neutral” rating by Citigroup on Wednesday, July 27. The stock of NiSource Inc. (NYSE:NI) has “Hold” rating given on Monday, April 25 by Evercore. The stock has “Neutral” rating by JP Morgan on Tuesday, March 29. The stock of NiSource Inc. (NYSE:NI) has “Hold” rating given on Wednesday, November 2 by Evercore. The stock has “Neutral” rating by UBS on Friday, July 8. The company was maintained on Friday, March 18 by Barclays Capital. The stock of NiSource Inc. (NYSE:NI) earned “Neutral” rating by Goldman Sachs on Thursday, December 15. On Monday, August 14 the stock rating was upgraded by Credit Suisse to “Outperform”. As per Thursday, October 13, the company rating was upgraded by Jefferies.

NiSource Inc. is an energy holding company. The company has market cap of $8.67 billion. The Firm is engaged in the distribution of natural gas. It has a 30.93 P/E ratio. The Firm operates through two business divisions: Gas Distribution Operations and Electric Operations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com